These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Genomics and Functional Genomics of Malignant Pleural Mesothelioma. Cakiroglu E; Senturk S Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882916 [TBL] [Abstract][Full Text] [Related]
5. Does Simian Virus 40 (SV40) Have a Role in UK Malignant Pleural Mesothelioma? No Role is Identified in a Sensitive RNA In Situ Hybridization Study on Potentially Affected Birth Cohorts. Alchami FS; Attanoos RL; Gibbs A; Morgan F; Jasani B Appl Immunohistochem Mol Morphol; 2020 Jul; 28(6):444-447. PubMed ID: 31205069 [TBL] [Abstract][Full Text] [Related]
6. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis. Bruno R; Alì G; Giannini R; Proietti A; Lucchi M; Chella A; Melfi F; Mussi A; Fontanini G Oncotarget; 2017 Jan; 8(2):2758-2770. PubMed ID: 27835874 [TBL] [Abstract][Full Text] [Related]
7. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects. Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567 [TBL] [Abstract][Full Text] [Related]
8. Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. Quetel L; Meiller C; Assié JB; Blum Y; Imbeaud S; Montagne F; Tranchant R; de Wolf J; Caruso S; Copin MC; Hofman V; Gibault L; Badoual C; Pintilie E; Hofman P; Monnet I; Scherpereel A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D Mol Oncol; 2020 Jun; 14(6):1207-1223. PubMed ID: 32083805 [TBL] [Abstract][Full Text] [Related]
9. Challenges in lung and thoracic pathology: molecular advances in the classification of pleural mesotheliomas. Fernandez-Cuesta L; Mangiante L; Alcala N; Foll M Virchows Arch; 2021 Jan; 478(1):73-80. PubMed ID: 33411030 [TBL] [Abstract][Full Text] [Related]
10. Incidence, mortality and survival in malignant pleural mesothelioma before and after asbestos in Denmark, Finland, Norway and Sweden. Hemminki K; Försti A; Chen T; Hemminki A BMC Cancer; 2021 Nov; 21(1):1189. PubMed ID: 34749677 [TBL] [Abstract][Full Text] [Related]
11. Epigenetic investigation into circulating microRNA 197-3p in sera from patients affected by malignant pleural mesothelioma and workers ex-exposed to asbestos. Di Mauro G; Frontini F; Torreggiani E; Iaquinta MR; Caselli A; Mazziotta C; Esposito V; Mazzoni E; Libener R; Grosso F; Maconi A; Martini F; Bononi I; Tognon M Sci Rep; 2023 Apr; 13(1):6501. PubMed ID: 37081052 [TBL] [Abstract][Full Text] [Related]
12. Malignant peritoneal mesotheliomas of rats induced by multiwalled carbon nanotubes and amosite asbestos: transcriptome and epigenetic profiles. Reamon-Buettner SM; Rittinghausen S; Klauke A; Hiemisch A; Ziemann C Part Fibre Toxicol; 2024 Jan; 21(1):3. PubMed ID: 38297314 [TBL] [Abstract][Full Text] [Related]
13. The role of epigenetics in malignant pleural mesothelioma. Vandermeers F; Neelature Sriramareddy S; Costa C; Hubaux R; Cosse JP; Willems L Lung Cancer; 2013 Sep; 81(3):311-318. PubMed ID: 23790315 [TBL] [Abstract][Full Text] [Related]
14. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. Kang HC; Kim HK; Lee S; Mendez P; Kim JW; Woodard G; Yoon JH; Jen KY; Fang LT; Jones K; Jablons DM; Kim IJ Oncotarget; 2016 Feb; 7(7):8321-31. PubMed ID: 26824986 [TBL] [Abstract][Full Text] [Related]
15. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers. Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620 [TBL] [Abstract][Full Text] [Related]
16. Upcoming epidemic of asbestos-related malignant pleural mesothelioma in Taiwan: A prediction of incidence in the next 30 years. Lin RT; Chang YY; Wang JD; Lee LJ J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):463-470. PubMed ID: 30072200 [TBL] [Abstract][Full Text] [Related]
17. BAP1 protein is a progression factor in malignant pleural mesothelioma. Arzt L; Quehenberger F; Halbwedl I; Mairinger T; Popper HH Pathol Oncol Res; 2014 Jan; 20(1):145-51. PubMed ID: 23963927 [TBL] [Abstract][Full Text] [Related]
18. [Asbestos and malignant pleural mesothelioma: molecular, cellular and physiopathological aspects]. Mohr S; Keith G; Rihn B Bull Cancer; 2005 Nov; 92(11):959-76. PubMed ID: 16316830 [TBL] [Abstract][Full Text] [Related]
19. The Association between Malignant Pleural Mesothelioma and Thoracic Radiation Therapy for Hodgkin's Lymphoma: The First Case Report in Japan. Nakashima K; Demura Y; Oi M; Tabata M; Tada T; Shiozaki K; Akai M; Ishizuka T Intern Med; 2021 Mar; 60(5):771-775. PubMed ID: 33055477 [TBL] [Abstract][Full Text] [Related]
20. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma. Betti M; Casalone E; Ferrante D; Aspesi A; Morleo G; Biasi A; Sculco M; Mancuso G; Guarrera S; Righi L; Grosso F; Libener R; Pavesi M; Mariani N; Casadio C; Boldorini R; Mirabelli D; Pasini B; Magnani C; Matullo G; Dianzani I Cancer Lett; 2017 Oct; 405():38-45. PubMed ID: 28687356 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]